Navigation Links
Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection

Effector T cells (Teff cells) are involved in activating and directing other immune cells, while regulatory T cells (Tregs) act to curb the over-aggressive responses of the T cell population.

Researchers continue to work on devising ways to mobilize anti-tumor Teff cells in order to better shape the immune response to tumors. Previously, James Allison and colleagues from Memorial Sloan-Kettering Cancer Center, New York, demonstrated that an anti–CTLA4 monocloncal antibody used in combination with a vaccine expressing GM-CSF (Gvax) was able to eradicate skin and breast cancer in mice. In a new study appearing online on June 15 in advance of print publication in the July issue of the Journal of Clinical Investigation, this same research group investigated the effects of CTLA4 blockade on the balance between Teff cells and Tregs during tumor rejection.

The authors show that when cancer develops in mouse skin cells, Tregs accumulate in tumors, yet CD8+ Teff cells are underrepresented. They go on to demonstrate that blockade of CTLA4 lifts the inhibition of T cell proliferation and allows both Tregs and Teff cells to proliferate in response to exposure to self-antigen. Interestingly, combination of CLTA4 blockade with Gvax selectively primes the anti-tumor Teff cells for action. This led to greater infiltration of Teff cells into the tumor, and eventually to tumor rejection. Importantly, the authors report that chronic exposure to anti- CLTA4 or to the Gvax/anti-CTLA4 combination therapy does not deplete the number of Tregs, nor their regulatory activity, which suggests that upon completion of this therapy these cells would still be able to control possible adverse immune responses.


'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. Combination therapy boosts effectiveness of telomere-directed cancer cell death
2. Combination therapy leads to partial recovery from spinal cord injury in rats
3. Combination therapy improves AIDS-related lymphoma outcome
4. Combination therapy shows promising results in patients with advanced lung cancer
5. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
6. Columbia research lifts major hurdle to gene therapy for cancer
7. Gene therapy converts dead bone graft to new, living tissue
8. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
9. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
10. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
11. New therapy for HIV/AIDS eliminates needles and excessive toxicity
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/16/2016)...   IdentyTechSolutions America LLC , a leading ... and a cutting-edge manufacturer of software and hardware ... seamless, integrated solutions that comprise IDT biometric readers ... provide IdentyTech,s customers with combined physical identification and ... and theft. "We are proud to ...
(Date:12/16/2016)... , Dec. 16, 2016 The global wearable medical device ... billion by 2021 from USD 5.31 billion in 2016, at a ... ... driven by technological advancements in medical devices, launch of a growing ... for wireless connectivity among healthcare providers, and increasing focus on physical ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
Breaking Biology News(10 mins):
(Date:1/14/2017)... ARLINGTON, Va. , Jan. 13, 2017  The ... following statement in response to FDA final guidance ... FDA for its continued leadership in emphasizing the importance ... members are keenly aware of the benefits biosimilars will ... costs.   Yet the portion of the ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... demand that it has found among its diverse customer base. The latest entry ... in most brands electroporators including BTX and Bio-Rad. FireflySci is introducing three distinct ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... short response times capable of performing routine electrochemical biosensing has increased dramatically. ... provide fast, sensitive detection and quantification of various analytes in complex samples. ...
(Date:1/12/2017)... 12, 2017   Protein Sciences Corporation , ... Flublok Influenza Vaccine ®, announced today that ... good safety results and induced strong neutralizing antibodies ... product is expected to advance into human clinical ... the Institute of Technology in Immunobiologicals of the ...
Breaking Biology Technology: